Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
New approaches in the management of multiple sclerosis.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Santhera to discontinue sale of Catena® in Canada
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Fourth PML Case With Tecfidera in MS Calls for Vigilance
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Phase 3 Study of RPC1063 in Relapsing MS
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Pharmacology and therapeutic potential of interferons.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
US court permits generic version of Teva MS drug a year sooner
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™

Pages